Logo image
Preexposure prophylaxis for the prevention of HIV transmission to women
Journal article   Open access   Peer reviewed

Preexposure prophylaxis for the prevention of HIV transmission to women

Erika Aaron and Deborah Cohan
AIDS (London), v 27(1), pp F1-F5
02 Jan 2013
PMID: 22914582
url
https://doi.org/10.1097/qad.0b013e32835917b4View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze) Open

Abstract

Immunology Infectious Diseases Life Sciences & Biomedicine Science & Technology Virology
The Food and Drug Administration (FDA) recently approved a new preexposure prophylaxis (PrEP) indication for emtricitabine/tenofovir for men and women, allowing a new effective HIV prevention intervention. Recent clinical trials have demonstrated the efficacy of PrEP in reducing the risk of HIV acquisition among women. Its efficacy depends largely on adherence. Perception of HIV risk appears to drive adherence to PrEP. What motivates PrEP use is specific to the population and its unique vulnerabilities. Future interventions exploring the efficacy of PrEP must include a behavioral arm that is specific to the unique vulnerabilities of the population being studied. There are an estimated 140 000 heterosexual serodiscordant couples in the United States; approximately, half of these couples desire conception. HIV-uninfected women in serodiscordant couples seeking conception may prove to be an ideal population for PrEP. Periconceptional PrEP in highly motivated couples could be not only effective but also affordable and feasible. In order to make PrEP accessible to those populations most vulnerable to HIV infection, the following steps need to occur: PrEP needs to be affordable, particularly for those uninsured; HIV providers, primary care practitioners, and reproductive healthcare providers need to welcome PrEP as a component of their scope of practice; clinicians need to take adequate sexual histories of all their patients in order to identify those at risk and best candidates for PrEP; and identifying ways to promote adherence must include population-specific PrEP adherence interventions. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:F1-F5

Metrics

2 Record Views
24 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Immunology
Infectious Diseases
Virology
Logo image